Epilepsy Treatment Market Analysis and Reports | Japan Conference Series

Market Analysis - Epilepsy Treatment 2018

                             4th World Congress on Epilepsy and Treatment

                                          November 16-17,2018  Tokyo, Japan

 Market value of Epilepsy globally

Epilepsy has important financial implications in terms of health care needs, premature death and lost work efficiency. An Indian study conducted in 1998 calculated that the cost per patient for treatment of epilepsy was as high as 88.2% of the country’s per capital Gross National Product and epilepsy-related costs, which included medical costs, travel, and lost work time, exceeded $2.6 billion per year (2013 USD). Annually NIH spends $30 billion for medical research, but ½ of 1% is only spent on epilepsy research although the social effects vary from country to country, the discrimination and social stigma which surround epilepsy in the world are often difficult to overcome than the seizures themselves. People having epilepsy may be targets of prejudice.

Seizures result in direct economic costs of about one billion dollars in the United States.  In India epilepsy is estimated to result in costs of 1.7 billion USD or 0.5% of the GDP. It is the cause of about 1% of emergency department visits (2% for emergency departments for children) in the United States. The estimated prevalence of active epilepsy (as of 2012) is in the range 3–10 per 1,000, with active epilepsy defined as someone with epilepsy who has had a least one unprovoked seizure in the last five years. Epilepsy is diagnosed in about 40-70 per lakh persons in developed countries and 80–140 per 100,000 in developing countries. Poverty is a risk and includes both being from a poor country and being poor relative to others within one's country.

Overview of the epilepsy drugs market

Extensive research carried out by the analysts at Technavio has shown that the global epilepsy drugs market will witness steady growth and will post a CAGR of more than 4% over the forecast period. The tentative approval of several late-stage pipeline molecules is one of the primary factors driving the growth of this market over the coming years. It has been observed that most of the drugs available in the market to treat epilepsy are only restricted to symptomatic treatment.

In terms of geography, the Americas led the global epilepsy drugs market and is likely to hold close to 50% of the revenue market shares by 2020. The growth of this market in the region is due to the high prevalence of the disorder and the availability of treatment options in the region, especially in the developed markets such as the US and Canada. Approximately 1% of the population in Canada has epilepsy, and 15,000 new cases are diagnosed each year.